France's Virbac Q3 revenue rises on strength in Both Companion Animal, Farm Animal segments

Virbac SA

19/10/2026 16:55

Overview
France animal health firm's Q3 revenue grew 8.8% at constant exchange rates and scope
YTD September 2026 revenue rose 7.9% at constant exchange rates and scope
Company confirmed 2026 guidance at upper end of revenue growth range

Outlook
Virbac targets upper end of 2026 revenue growth range of 5.5% to 7.5% at CERS
Company expects 2026 adjusted recurring operating income margin of around 17% at CERS
Virbac does not anticipate material impact from inflation or Middle East risks on 2026 outlook

Result Drivers
SEGMENT GROWTH - Both Companion Animal (+8.8%) and Farm Animal (+7.0%) segments contributed to revenue growth, with Supercharge platforms (excluding Thyronorm) up about 11% at constant rates and scope
VOLUME AND PRICING - Strong volume/mix effect of about +6%, supplemented by price increases of about +2%
THYRONORM ACQUISITION - Thyronorm acquisition contributed 1.3 percentage points to overall growth year to date

Company press release: ID:nGNE15rcZc

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
 
EUR 400 mln
 

Reuters Recommended Reads
Oct 19 - Roche puts future German investments 'on hold'
Oct 19 - China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)